Action TH THERATECHNOLOGIES INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Theratechnologies Inc.

Actions

TH

CA88338H7040

Marché Fermé - Toronto S.E.
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
1,8 CAD 0,00% Graphique intraday de Theratechnologies Inc. -0,55% -15,89%
10/04 Mise à jour sur Theratechnologies ; baisse de plus de 5 % à la Bourse de Toronto en raison de la réduction de la perte nette au premier trimestre et de l'attente de la décision de la FDA MT
10/04 Theratechnologies en hausse de près de 6 % sur le marché préliminaire américain après la réduction de sa perte nette au premier trimestre et l'accélération de l'essai de phase 1 d'un médicament contre le cancer de l'ovaire MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug
Theratechnologies: Fiscal Q1 Earnings Snapshot
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024
North American Morning Briefing : Traders Await -2-
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform
Theratechnologies Appoints Elina Tea to its Board of Directors
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform
Theratechnologies Brief: To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TH
  4. Actualités Theratechnologies Inc.
  5. Autres langues